Sygnature’s new office a platform to launch US growth ‘campaign’
The new office is located in Cambridge, MA, near Kendall Square. According to the company, there are more than 100 pharma/biotech firms within a mile of the new office.
“The Boston/Cambridge area is probably the place in the world with the highest density of biotechs, pharma organizations, and top tier universities all in one place,” said Andy Lindstrom, director of marketing. “We already have clients there, but in the interest of expanding our client base locally and better serving our customers across the USA, we wanted to be as close as possible to them.”
Sygnature’s revenue from the US already accounts for more than 50% of our sales, explained Paul Clewlow, senior vice president of business development.
“In recent years, we have seen a considerable increase in demand for our integrated drug discovery and preclinical services,” he told us. This growth is being driven by a greater awareness of the company and its services, Clewlow said.
“Moreover, the pharmaceutical industry is very connected,” he said, “people talk and the word spreads about Sygnature, so the many successful projects we have delivered are in that way leading to more work for us, particularly in the US.”
The company also has seen an increased diversity of its US clients, with growing demand from various organizations “that are on the cutting-edge of drug discovery in various therapeutic areas,” said Clewlow. These customers range from biotech start-ups, major pharma companies, to academia and novel materials technology companies, he said.
“We see our new Kendall Square base as a platform to launch Sygnature’s campaign to sustainably grow our US presence and multiply our sales in the coming years,” Clewlow added.
The company added a new facility at Alderley Park in Cheshire, UK in August 2018, after which it implanted a recruitment program and doubled the size of its drug metabolism and pharmacokinetics (DMPK) department.
